Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.41 |
| ▸ | FNTB | P49356 | 12/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.40 |
| ▸ | NPY1R | P25929 | 3/20 | 0.40 |
| ▸ | NPY4R | P50391 | 3/20 | 0.40 |
| ▸ | GRPR | P30550 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638080 | 0.93 | NPY4R (0.43) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL29608915 | 0.91 | NPY4R (0.43) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL29638063 | 0.89 | NPY4R (0.43) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL27823626 | 0.89 | FNTA (0.50) | FNTAFNTBPGGT1BNPY5RNPY1R | |
| SCHEMBL29701964 | 0.89 | FNTA (0.50) | FNTAFNTBPGGT1BNPY5RNPY1R | |
| SCHEMBL29638076 | 0.88 | NPY4R (0.42) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL29355526 | 0.88 | NPY4R (0.46) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL30943801 | 0.86 | FNTA (0.48) | FNTAFNTBPGGT1BNPY5RNPY1R | |
| SCHEMBL29414400 | 0.86 | NPY4R (0.43) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL31544459 | 0.85 | FNTA (0.47) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4591934-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4523749-A2 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12214015-B2 | Use of c-type natriuretic peptide variants to treat osteoarthritis | BIOMARIN PHARMACEUTICAL INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4029512-A1 | VARIANTS OF C-TYPE NATRIURETIC PEPTIDE | BioMarin Pharmaceutical Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4019038-A2 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BioMarin Pharmaceutical Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220160836-A1 | USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS | BIOMARIN PHARMACEUTICAL INC. | 2022-05-26 | — | — | US | disclosed |